A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.

Publication

A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.

Journal Paper/Review - Jan 15, 2024

Mastall Maximilian, Roth Patrick, Bink Andrea, Maranta Angela Fischer, Läubli Heinz, Hottinger Andreas Felix, Hundsberger Thomas, Migliorini Denis, Ochsenbein Adrian F, Seystahl Katharina, Imbach Lukas L, Hortobágyi Tibor, Held Leonhard, Weller Michael, Wirsching Hans-Georg

Citation

Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC cancer 2024; 24:82.

Type

Journal Paper/Review (English)

Journal

BMC cancer 2024; 24

Publication Date

Jan 15, 2024

Issn Electronic

1471-2407

Brief description/objective

Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks interconnect with glioblastoma cell networks through glutamatergic neuroglial synapses, activation of which induces oncogenic calcium oscillations that are propagated via gap junctions between tumor cells. The primary objective of this study is to explore the efficacy of brain-penetrating anti-glutamatergic drugs to standard chemoradiotherapy in patients with glioblastoma.